Literature DB >> 6135619

Structure-activity requirements for hypotension and alpha-adrenergic receptor blockade by analogues of atropine.

E H Cantor, S Abraham, E A Marcum, S Spector.   

Abstract

The hypotensive action of various antimuscarinic compounds structurally related to atropine was studied in conscious, unanesthetized rats. The alpha-adrenolytic activity of these agents was assessed both in vivo (blockade of norepinephrine-induced pressor response) and in vitro (displacement of [3H]WB-4101 binding). Benztropine, homatropine and hyoscyamine caused hypotension and produced alpha-adrenergic receptor blockade similar to atropine. Other analogues were either inactive (atroscine, scopolamine, tropic acid and tropine) or evoked nonspecific changes in blood pressure and lacked alpha-adrenolytic activity (benactyzine, eucatropine, methylatropine, methylhomatropine and methylscopolamine). Based on these data, we propose the following structure-activity relationship for hypotension and alpha-adrenolytic activity: (a) the tropine moiety is inactive unless it is attached to another group by an ester linkage, (b) chemical modification of the tropine moiety, including quaternization, decreases potency, (c) the d-stereoisomer appears to be more potent than the corresponding 1-form.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135619     DOI: 10.1016/0014-2999(83)90215-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Adrenoceptor blocking properties of atropine-like agents anisodamine and anisodine on brain and cardiovascular tissues of rats.

Authors:  D R Varma; T L Yue
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

2.  The contributions of muscarinic receptors and changes in plasma aldosterone levels to the anti-hypertensive effect of Tulbaghia violacea.

Authors:  Ismaila Raji; Pierre Mugabo; Kenechukwu Obikeze
Journal:  BMC Complement Altern Med       Date:  2013-01-11       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.